Medicine doctor and stethoscope in hand

Next-Generation Point-of-Care Solution

A Lab In Your Hand

Proxim has developed a next-generation handheld immunodiagnostic device. The system performs the most important laboratory tests near the patient using whole blood without any sacrifice in sensitivity and precision, bringing the most critical information to the doctors right when they need it. The instrument is battery operated, has touch-screen display interface, wireless, Ethernet, and USB connectivity.

 

Point-of-Care vs. Central Lab

System Features

Cartridge Features

Special attention was given to the disposable test cartridge, which can be manufactured at a low cost. Proxim’s unique combination of high performance and low cost not only make it ideal for hospital emergency departments in the USA but also in other settings around the world.​

Test Menu

Sepsis

Cardiology

Infectious Disease

 

Procalcitonin (PCT)

According to CDC, every year at least 1.7 millions American adults develop sepsis and early 270,000 dies. For each hour sepsis treatment is delayed, the patient's risk of death increases by 4 percent, making our point-of-care solution especially valuable. PCT allows differentiation of patients where sepsis is caused by bacterial infection.

 

Measurement range: 0.01 ng/ml .. 30 ng/ml

Resources

  1. Fischer et al, "Development of an IL-6 point-of-care assay: utility for real-time monitoring and management of cytokine release syndrome and sepsis", Bioanalysis, (2019).

  2. Wacker et al, "Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis", The Lancet, (2013).

  3. Del Valle et al, "An inflammatory cytokine signature predicts COVID-19 severity and survival", Nature Medicine, (2020).

  4. Apple and Collinson, "Analytical characteristics of high-sensitivity cardiac troponin assays", Clinical Chemistry, (2012).

  5. Proxim internal studies with whole blood using multiple instruments and cartridge lots.

  6. Weber and Hamm, "Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine", Heart, (2006).

  7. Wells et al, "Evaluation of D-Dimer in the diagnosis of suspected deep-vein thrombosis", New England J. of Medicine, (2003).

  8. Young et al, "Clinical evaluation of BD Veritor SARS-CoV-2 point-of-care test performance compared to PCR-based testing and versus the Sofia 2 SARS Antigen point-of-care test", Virology, (2020). 

Management Team

Mikhail-2016.jpg

Mikhail Briman

CEO, Co-Founder, Board Director

PhD in Physics, UCLA

Constantly inventing and developing sensor technologies. Driven to transform technology into products that can be made inexpensively and that people will want to use.

Vikram.jfif

Vikram Joshi

Co-Founder, Board Director

MBA, Wharton & MS, Stanford

Passion for advanced materials and their applications. Goal is to get better and cheaper treatments into the hands of healthcare providers around the globe.

Sergey-2.jfif

Sergey Belonozhko

Board Chairman

MBA, University of Chicago

Angel investor in healthcare companies. Senior customer relationships executive with extensive knowledge of complex telco solutions and working with global clients.

Tom.jfif

Thomas Shannon

Board Director

CFP, ChFC, BA in Finance, University of Wisconsin

Angel investor and board member of multiple startup companies. President & CEO of BrightStar Wisconsin Foundation, ex-CEO of Prodesse (sold to Gen-Probe).

 
 

Contact us

hello@proximdx.com

Proxim Diagnostics Corp.
2065 Martin Ave Ste 101
Santa Clara, CA 95050, USA

The product has not been cleared for sale by the US FDA. At this time it is available for research use only.

 © 2020 by Proxim Diagnostics Corp.